User:Mr. Ibrahem/Mesalazine
 | |
| Clinical data | |
|---|---|
| Trade names | Asacol, Lialda, Pentasa, others[1] |
| Other names | mesalamine, 5-aminosalicylic acid, 5-ASA, Mesalazine (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a688021 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, rectal |
| Drug class | Aminosalicylate[1][3] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | orally: 20–30% absorbed rectally: 10–35% |
| Metabolism | Rapidly & extensively metabolised intestinal mucosal wall and the liver |
| Elimination half-life | 5 hours after initial dose. At steady state 7 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C7H7NO3 |
| Molar mass | 153.137 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 283 °C (541 °F) |
| |
| |
| (verify) | |
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease.[1] It is generally used for mildly to moderately severe disease.[1] It is taken by mouth or rectally.[1] The formulations which are taken by mouth appear to be similarly effective.[3]
Common side effects include headache, nausea, abdominal pain, and fever.[1] Serious side effects may include pericarditis, liver problems, and kidney problems.[1][3] Use in pregnancy and breastfeeding appears safe.[3] In people with a sulfa allergy certain formulations may result in problems.[1] Mesalazine is an aminosalicylate and anti-inflammatory.[1][3] It works by direct contact with the intestines.[1]
Mesalazine was approved for medical use in the United States in 1987.[1][5] It is available as a generic medication and sold under many brand names worldwide.[1][6] A month supply in the United Kingdom costs the NHS less than £30 as of 2021.[3] In the United States the wholesale cost of this amount is about 288 USD.[7] In 2017, it was the 246th most commonly prescribed medication in the United States, with more than one million prescriptions.[8][9]
References[edit]
- ^ a b c d e f g h i j k l m n "Mesalamine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists.
- ^ a b "Mesalamine Use During Pregnancy". Drugs.com. 18 September 2018. Retrieved 30 December 2019.
- ^ a b c d e f "1. Gastro-intestinal system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 44–47. ISBN 978-0-85711-413-6.
{{cite book}}: CS1 maint: date format (link) - ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020.
- ^ "Asacol HD- mesalamine tablet, delayed release". DailyMed. 15 April 2018. Retrieved 30 December 2019.
- ^ "ANDA Approval Reports - 2017 First Generic Drug Approvals". Food and Drug Administration (FDA). Retrieved 8 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Mesalamine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.